Page 4 - Numinus Bioscience News Today

/PRNewswire/ - Numinus Wellness Inc. ("Numinus", the "Company") (TSX: NUMI) (OTCQX: NUMIF) today announces the mailing of its management information circular...

The medicinal use of hallucinogenic mushrooms is making inroads in U.S. states as military veterans advocate for the therapeutic value of psychedelic drugs.

The medicinal use of hallucinogenic mushrooms is making inroads in U.S. states as military veterans advocate for the therapeutic value of psychedelic drugs.

The medicinal use of hallucinogenic mushrooms is making inroads in U.S. states as military veterans advocate for the therapeutic value of psychedelic drugs.

Numinus Wellness Inc. (OTCPK:NUMIF) Q2 2022 Results Conference Call April 14, 2022 05:30 PM ET Company Participants Jamie Kokoska - VP, IR Payton Nyquvest - Founder and CEO John Fong - CFO...

Revenues grew 240% year-over-year to $0.8 million for the quarter Achieved 29.1% gross margin during Q2 2022, compared to 6.5% in Q1 2022, due to a larger...

Numinus Wellness CEO Payton Nyquvest joined Steve Darling from Proactive to share news the company has made a major acquisition bringing leading mental...

Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one...

• Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory• Shared mission of responsibly

FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, March 30, 2022 /PRNewswire/ -- Depression and anxiety affect millions around the world and the venom of a toad is the